These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33843197)

  • 21. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
    Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
    mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-promoting properties of
    Ansari F; Alian Samakkhah S; Bahadori A; Jafari SM; Ziaee M; Khodayari MT; Pourjafar H
    Crit Rev Food Sci Nutr; 2023; 63(4):457-485. PubMed ID: 34254862
    [No Abstract]   [Full Text] [Related]  

  • 23. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition.
    Rodríguez-Nogales A; Algieri F; Garrido-Mesa J; Vezza T; Utrilla MP; Chueca N; García F; Rodríguez-Cabezas ME; Gálvez J
    J Nutr Biochem; 2018 Nov; 61():129-139. PubMed ID: 30236870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saccharomyces boulardii alleviates allergic asthma by restoring gut microbiota and metabolic homeostasis via up-regulation of METTL3 in an m6A-dependent manner.
    Liu D; Hu L; Yang Y; Wang Y; Li Y; Su J; Wang G; Gong S
    Immunol Lett; 2024 Jun; 267():106853. PubMed ID: 38513836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
    Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
    Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Briand F; Sulpice T; Giammarinaro P; Roux X
    Benef Microbes; 2019 May; 10(5):555-567. PubMed ID: 31090460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A teaching protocol demonstrating the use of EasyClone and CRISPR/Cas9 for metabolic engineering of Saccharomyces cerevisiae and Yarrowia lipolytica.
    Milne N; Tramontin LRR; Borodina I
    FEMS Yeast Res; 2020 Mar; 20(2):. PubMed ID: 31556952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of fructooligosaccharides and Saccharomyces boulardii on the compositional structure and metabolism of gut microbiota in students.
    Fu H; Chen Z; Teng W; Du Z; Zhang Y; Ye X; Yu Z; Zhang Y; Pi X
    Microbiol Res; 2024 Aug; 285():127741. PubMed ID: 38761487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
    Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
    Gut Microbes; 2017 Jan; 8(1):17-32. PubMed ID: 27973989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual regulation of lipid droplet-triacylglycerol metabolism and ERG9 expression for improved β-carotene production in Saccharomyces cerevisiae.
    Bu X; Lin JY; Duan CQ; Koffas MAG; Yan GL
    Microb Cell Fact; 2022 Jan; 21(1):3. PubMed ID: 34983533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a controllable β-carotene biosynthetic pathway by decentralized assembly strategy in Saccharomyces cerevisiae.
    Xie W; Liu M; Lv X; Lu W; Gu J; Yu H
    Biotechnol Bioeng; 2014 Jan; 111(1):125-33. PubMed ID: 23860829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
    Cui B; Lin L; Wang B; Liu W; Sun C
    Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota.
    Gu Y; Wang C; Qin X; Zhou B; Liu X; Liu T; Xie R; Liu J; Wang B; Cao H
    Pharmacol Res; 2022 Jul; 181():106291. PubMed ID: 35690329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.
    Villar-García J; Güerri-Fernández R; Moya A; González A; Hernández JJ; Lerma E; Guelar A; Sorli L; Horcajada JP; Artacho A; D Auria G; Knobel H
    PLoS One; 2017; 12(4):e0173802. PubMed ID: 28388647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii.
    Datta S; Timson DJ; Annapure US
    J Sci Food Agric; 2017 Jul; 97(9):3039-3049. PubMed ID: 27868205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline.
    Roy Sarkar S; Mitra Mazumder P; Chatterjee K; Sarkar A; Adhikary M; Mukhopadhyay K; Banerjee S
    Physiol Behav; 2021 Jul; 236():113411. PubMed ID: 33811908
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Albuquerque RCMF; Brandão ABP; De Abreu ICME; Ferreira FG; Santos LB; Moreira LN; Taddei CR; Aimbire F; Cunha TS
    Benef Microbes; 2019 Dec; 10(8):901-912. PubMed ID: 31965836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of point and structural mutations in engineered yeast Saccharomyces cerevisiae improve carotenoid production.
    Yamada R; Ando K; Sakaguchi R; Matsumoto T; Ogino H
    World J Microbiol Biotechnol; 2024 Jun; 40(7):230. PubMed ID: 38829459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Novel ATP Bioluminescence Assay Based on Engineered Probiotic
    Park JS; Kim YW; Kim H; Kim SK; Park K
    J Microbiol Biotechnol; 2023 Nov; 33(11):1506-1512. PubMed ID: 37482802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic engineering of Saccharomyces cerevisiae for production of β-carotene from hydrophobic substrates.
    Fathi Z; Tramontin LRR; Ebrahimipour G; Borodina I; Darvishi F
    FEMS Yeast Res; 2021 Jan; 21(1):. PubMed ID: 33332529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.